These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26589198)

  • 21. Deconstructing age reprogramming.
    Singh PB; Laktionov PP; Newman AG
    J Biosci; 2019 Sep; 44(4):. PubMed ID: 31502583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induced pluripotent stem cells reprogramming: Epigenetics and applications in the regenerative medicine.
    Gomes KM; Costa IC; Santos JF; Dourado PM; Forni MF; Ferreira JC
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):180-189. PubMed ID: 28355380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
    Matsuda Y; Semi K; Yamada Y
    Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in Therapeutic Applications of Induced Pluripotent Stem Cells.
    Rami F; Beni SN; Kahnamooi MM; Rahimmanesh I; Salehi AR; Salehi R
    Cell Reprogram; 2017 Apr; 19(2):65-74. PubMed ID: 28266864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic Control of Reprogramming and Transdifferentiation by Histone Modifications.
    Qin H; Zhao A; Zhang C; Fu X
    Stem Cell Rev Rep; 2016 Dec; 12(6):708-720. PubMed ID: 27623868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering cell fate: Spotlight on cell-activation and signaling-directed lineage conversion.
    Ebrahimi B
    Tissue Cell; 2016 Oct; 48(5):475-87. PubMed ID: 27514850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct cell reprogramming: approaches, mechanisms and progress.
    Wang H; Yang Y; Liu J; Qian L
    Nat Rev Mol Cell Biol; 2021 Jun; 22(6):410-424. PubMed ID: 33619373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in silico profiling of epigenetic modifiers in human tissues.
    Son MY; Jung CR; Kim DS; Cho HS
    Mol Biol Rep; 2018 Jun; 45(3):309-314. PubMed ID: 29626316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status in cancer cell reprogramming and its clinical implications.
    Izgi K; Canatan H; Iskender B
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcription factor-mediated reprogramming: epigenetics and therapeutic potential.
    Firas J; Liu X; Lim SM; Polo JM
    Immunol Cell Biol; 2015 Mar; 93(3):284-9. PubMed ID: 25643615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
    Chhabra A
    Stem Cell Rev Rep; 2017 Dec; 13(6):757-773. PubMed ID: 28918520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concise review: Induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart?
    Bilic J; Izpisua Belmonte JC
    Stem Cells; 2012 Jan; 30(1):33-41. PubMed ID: 22213481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic aberrations in human pluripotent stem cells.
    Bar S; Benvenisty N
    EMBO J; 2019 Jun; 38(12):. PubMed ID: 31088843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The miR-302-Mediated Induction of Pluripotent Stem Cells (iPSC): Multiple Synergistic Reprogramming Mechanisms.
    Ying SY; Fang W; Lin SL
    Methods Mol Biol; 2018; 1733():283-304. PubMed ID: 29435941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of small molecules on cell reprogramming.
    Baranek M; Belter A; Naskręt-Barciszewska MZ; Stobiecki M; Markiewicz WT; Barciszewski J
    Mol Biosyst; 2017 Jan; 13(2):277-313. PubMed ID: 27918060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical compound-based direct reprogramming for future clinical applications.
    Takeda Y; Harada Y; Yoshikawa T; Dai P
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29739872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular reprogramming and cancer development.
    Semi K; Matsuda Y; Ohnishi K; Yamada Y
    Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
    Semi K; Yamada Y
    Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic memory in reprogramming.
    Hörmanseder E
    Curr Opin Genet Dev; 2021 Oct; 70():24-31. PubMed ID: 34058535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Cellular Extract on Epigenetic Reprogramming.
    Xiong XR; Lan DL; Li J; Yin S; Xiong Y; Zi XD
    Cell Reprogram; 2019 Jun; 21(3):115-121. PubMed ID: 31084436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.